205 related articles for article (PubMed ID: 19755386)
1. Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Ngo HT; Azab AK; Farag M; Jia X; Melhem MM; Runnels J; Roccaro AM; Azab F; Sacco A; Leleu X; Anderson KC; Ghobrial IM
Clin Cancer Res; 2009 Oct; 15(19):6035-41. PubMed ID: 19755386
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.
Muz B; de la Puente P; Azab F; Ghobrial IM; Azab AK
Mol Cancer Res; 2015 Feb; 13(2):263-72. PubMed ID: 25232031
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
5. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
[TBL] [Abstract][Full Text] [Related]
6. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia.
Azab F; Azab AK; Maiso P; Calimeri T; Flores L; Liu Y; Quang P; Roccaro AM; Sacco A; Ngo HT; Zhang Y; Morgan BL; Carrasco RD; Ghobrial IM
Clin Cancer Res; 2012 Jan; 18(1):91-104. PubMed ID: 22010211
[TBL] [Abstract][Full Text] [Related]
7. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Anticancer Ther; 2015; 15(10):1143-56. PubMed ID: 26196236
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation.
Azab AK; Azab F; Quang P; Maiso P; Sacco A; Ngo HT; Liu Y; Zhang Y; Morgan BL; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Jul; 17(13):4389-99. PubMed ID: 21521775
[TBL] [Abstract][Full Text] [Related]
10. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
11. Targeting the bone marrow in Waldenstrom macroglobulinemia.
Ghobrial IM; Zhang Y; Liu Y; Ngo H; Azab F; Sacco A; Azab A; Maiso P; Morgan B; Quang P; Issa GC; Leleu X; Roccaro AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(Suppl 1):S65-9. PubMed ID: 22035751
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
de Rooij MF; Kuil A; Kraan W; Kersten MJ; Treon SP; Pals ST; Spaargaren M
Haematologica; 2016 Mar; 101(3):e111-5. PubMed ID: 26635033
[No Abstract] [Full Text] [Related]
13. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
14. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Leleu X; Jia X; Runnels J; Ngo HT; Moreau AS; Farag M; Spencer JA; Pitsillides CM; Hatjiharissi E; Roccaro A; O'Sullivan G; McMillin DW; Moreno D; Kiziltepe T; Carrasco R; Treon SP; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
Blood; 2007 Dec; 110(13):4417-26. PubMed ID: 17761832
[TBL] [Abstract][Full Text] [Related]
15. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
[TBL] [Abstract][Full Text] [Related]
16. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
[TBL] [Abstract][Full Text] [Related]
17. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.
Ngo HT; Leleu X; Lee J; Jia X; Melhem M; Runnels J; Moreau AS; Burwick N; Azab AK; Roccaro A; Azab F; Sacco A; Farag M; Sackstein R; Ghobrial IM
Blood; 2008 Jul; 112(1):150-8. PubMed ID: 18448868
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
19. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
20. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]